[HTML][HTML] Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study
M Rinaldi, C Campoli, M Gallo, D Marzolla… - BMC Infectious …, 2023 - Springer
Purpose To investigate the clinical impact of three available antivirals for early COVID-19
treatment in a large real-life cohort. Methods Between January and October 2022 all …
treatment in a large real-life cohort. Methods Between January and October 2022 all …
[HTML][HTML] Efficacy and safety of nirmatrelvir/ritonavir, molnupiravir, and remdesivir in a real-world cohort of outpatients with COVID-19 at high risk of progression: the …
G Tiseo, C Barbieri, V Galfo, S Occhineri… - Infectious Diseases and …, 2023 - Springer
Introduction Different antivirals are available for the treatment of outpatients with COVID-19.
Our aim was to describe a real-world experience of outpatient management of COVID-19 …
Our aim was to describe a real-world experience of outpatient management of COVID-19 …
Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a …
S Rajme-López, BA Martinez-Guerra… - Therapeutic …, 2024 - journals.sagepub.com
Background: Even though worldwide death rates from coronavirus disease 2019 (COVID-
19) have decreased, the threat of disease progression and death for high-risk groups …
19) have decreased, the threat of disease progression and death for high-risk groups …
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis
M Zur, T Peselev, S Yanko, V Rotshild, I Matok - Antiviral Research, 2023 - Elsevier
Background Remdesivir, molnupiravir, and nirmatrelvir/ritonavir are three antiviral agents
approved by FDA emergency authorization for treating mild to moderate symptomatic COVID …
approved by FDA emergency authorization for treating mild to moderate symptomatic COVID …
[HTML][HTML] Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation study
Background Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for
COVID-19 treatment, but direct comparisons of their effectiveness have been limited. This …
COVID-19 treatment, but direct comparisons of their effectiveness have been limited. This …
[HTML][HTML] Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system
Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
[HTML][HTML] Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or …
F Bai, T Beringheli, V Vitaletti, A Santoro, F Molà… - Infectious Diseases and …, 2024 - Springer
Introduction We compared the effectiveness and virological clearance (VC) at day 7 (T7)
post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2 …
post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2 …
[HTML][HTML] Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter …
X Han, D Gao, C Li, X Yuan, J Cui, W Zhao, F Xie… - BMC Infectious …, 2024 - Springer
Background and aim Two oral antivirals (Nirmatrelvir-ritonavir and Azvudine) are widely
used in China practice during the Omicron wave of the pandemic. However, little evidence …
used in China practice during the Omicron wave of the pandemic. However, little evidence …
[PDF][PDF] Antiviral treatment in COVID-19 outpatients: a systematic review of randomized controlled trials
Background: Most COVID-19 patients have mild or moderate illnesses that can progress to
severe illness, leading to hospitalization and/or mortality. The use of antivirals to prevent the …
severe illness, leading to hospitalization and/or mortality. The use of antivirals to prevent the …
Nirmatrelvir–Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak: Real-World Evidence from Beijing
Y Zhang, X Wang, C Huang, H Yang… - Infection and Drug …, 2024 - Taylor & Francis
Objective The efficacy of nirmatrelvir–ritonavir for hospitalized patients with COVID-19 has
not been fully established. Methods We conducted a retrospective analysis of hospitalized …
not been fully established. Methods We conducted a retrospective analysis of hospitalized …